U.S. Markets close in 5 hrs 52 mins

Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
173.41-0.26 (-0.15%)
As of 10:08AM EDT. Market open.
People also watch
BIIBGILDCELGMRKBMY
Full screen
Previous Close173.67
Open173.02
Bid173.65 x 200
Ask173.74 x 100
Day's Range172.42 - 173.87
52 Week Range133.64 - 184.21
Volume307,517
Avg. Volume3,504,318
Market Cap127.53B
Beta1.76
PE Ratio (TTM)16.47
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.67%)
Ex-Dividend Date2017-05-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion
    Zacks47 minutes ago

    Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion

    Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism

  • 24/7 Wall St.1 hour ago

    Major Biotech Short Interest Surges

    The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.

  • Reuters9 hours ago

    Novartis gets European OK for biosimilar of Amgen's Enbrel

    Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. The approval was based on a development programme that demonstrated that Erelzi, a biosimilar of the drug also known as etanercept, matches its reference medicine in terms of safety, efficacy, and quality, Sandoz said in a statement on Tuesday.